#1 Clinical Trials Search in Europe

Tolcapone

Tolcapone, also known by its brand name Tasmar, is a medication that has been the subject of numerous clinical trials for its potential in treating various medical conditions. Originally developed for Parkinson’s disease, researchers are now investigating its efficacy in addressing a range of disorders, from rare genetic diseases to cognitive and behavioral issues. This article delves into the ongoing studies and potential applications of Tolcapone across different medical fields.

Table of Contents

What is Tolcapone?

Tolcapone is a medication that belongs to a class of drugs called catechol-O-methyltransferase (COMT) inhibitors. It is also known by the brand name Tasmar[1]. Tolcapone works by affecting certain chemicals in the brain, particularly dopamine, which is important for various brain functions.

Medical Conditions Treated with Tolcapone

Tolcapone is primarily used to treat several medical conditions:

  • Parkinson’s Disease: Tolcapone is approved for use in combination with levodopa and carbidopa to treat Parkinson’s disease symptoms[1].
  • Transthyretin Amyloidosis (ATTR): This is a rare genetic disease where abnormal protein deposits form in various organs. Researchers are studying tolcapone’s potential to stabilize the problematic protein in ATTR[1].
  • Cognitive Disorders: Studies are exploring tolcapone’s effects on cognitive function in conditions like schizophrenia and neurocognitive disorders[5][9].
  • Obsessive-Compulsive Disorder (OCD): Research is being conducted to evaluate tolcapone’s efficacy in treating moderate to severe OCD[7].
  • Pathological Gambling: Some studies have investigated tolcapone’s potential in reducing gambling urges[3].

How Tolcapone Works

Tolcapone works by inhibiting an enzyme called catechol-O-methyltransferase (COMT). This enzyme is responsible for breaking down certain neurotransmitters, including dopamine. By inhibiting COMT, tolcapone helps to increase the levels of dopamine in the brain[9].

In Parkinson’s disease, this mechanism helps to prolong the effects of levodopa, a primary treatment for the condition. For other disorders, the increased dopamine levels may help improve cognitive function and reduce certain symptoms[5].

Dosage and Administration

The dosage of tolcapone can vary depending on the condition being treated and individual patient factors. Here are some general guidelines based on the clinical trials:

  • For Parkinson’s disease: Typically, 100mg or 200mg three times a day[1].
  • For research studies: Doses ranged from 100mg to 300mg per day, often divided into multiple doses[3][5].
  • In some studies, the dose was gradually increased over time[1].

It’s crucial to note that tolcapone should only be taken under the supervision of a healthcare professional, who will determine the appropriate dosage for each individual patient.

Potential Side Effects

As with any medication, tolcapone can cause side effects. While not everyone experiences side effects, it’s important to be aware of potential issues. Common side effects may include:

  • Nausea
  • Diarrhea
  • Fatigue
  • Dizziness
  • Headache

More serious side effects can occur, particularly related to liver function. Regular liver function tests are typically required for patients taking tolcapone[5]. Always report any unusual symptoms or side effects to your healthcare provider.

Ongoing Research and Future Potential

Tolcapone is the subject of ongoing research for various conditions:

  • Transthyretin Amyloidosis: Studies are investigating tolcapone’s ability to stabilize the transthyretin protein, potentially slowing disease progression[1].
  • Cognitive Enhancement: Researchers are exploring tolcapone’s effects on cognitive function in both healthy individuals and those with conditions like schizophrenia[5][9].
  • Obsessive-Compulsive Disorder: Clinical trials are assessing tolcapone’s efficacy in treating OCD symptoms[7].
  • Sleep and Vigilance: Some studies are looking at how tolcapone affects vigilance and cognitive performance during sleep deprivation[8].

These ongoing studies may lead to new approved uses for tolcapone in the future, potentially benefiting patients with a variety of conditions.

Aspect Details
Primary Conditions Studied Transthyretin Amyloidosis, Schizophrenia, Pathological Gambling, Traumatic Brain Injury, Obsessive-Compulsive Disorder
Common Dosages 100-200mg, taken 2-3 times daily
Administration Method Oral tablets (some studies exploring modified release formulations)
Trial Durations Ranging from 7 days to 8 weeks
Key Outcome Measures TTR stabilization, cognitive function, symptom severity scales (e.g., YBOCS), pharmacokinetic parameters
Notable Secondary Outcomes Effects on mood, quality of life, brain activation patterns (fMRI)
Genetic Considerations Some studies examining impact of Val-158-Met polymorphism on treatment response

FAQ

  • What is Tolcapone and how does it work? Tolcapone is a medication that works as a catechol-O-methyl transferase (COMT) inhibitor. It helps increase the levels of certain neurotransmitters in the brain, particularly dopamine. This mechanism of action makes it potentially useful for various neurological and psychiatric conditions.
  • What conditions are being studied with Tolcapone in clinical trials? Clinical trials are exploring Tolcapone's potential in treating a variety of conditions, including Transthyretin Amyloidosis, schizophrenia, pathological gambling, traumatic brain injury, obsessive-compulsive disorder, and cocaine-related disorders. It's also being studied for its effects on cognitive function and vigilance.
  • How is Tolcapone administered in these trials? In most trials, Tolcapone is administered orally in tablet form. The dosage varies depending on the study, but common doses range from 100mg to 200mg, taken two to three times daily. Some studies are also exploring modified release formulations of Tolcapone.
  • What are the potential side effects of Tolcapone? While specific side effects can vary depending on the condition being treated and individual factors, common side effects may include nausea, diarrhea, and liver function changes. It's important to note that all clinical trials closely monitor participants for any adverse effects.
  • How long do Tolcapone clinical trials typically last? The duration of Tolcapone trials varies widely depending on the study design and objectives. Some trials last just a few weeks, while others may extend to several months. For example, some studies in the data provided lasted from 7 days to 8 weeks.

Ongoing Clinical Trials on Tolcapone

  • Study on Tolcapone for Improving Cognitive Symptoms in Patients with Long-Standing Schizophrenia

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Transthyretin Amyloidosis (ATTR): A rare genetic disorder characterized by the buildup of abnormal deposits of a protein called amyloid in the body's organs and tissues.
  • Catechol-O-methyl transferase (COMT): An enzyme that breaks down certain neurotransmitters in the brain, including dopamine. Tolcapone works by inhibiting this enzyme.
  • Leptomeningeal: Referring to the two innermost layers of tissues (pia mater and arachnoid mater) that cover the brain and spinal cord.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Cognitive flexibility: The ability to adapt one's thinking or behavior in response to changing situations or environments.
  • Yale Brown Obsessive Compulsive Scale (YBOCS): A clinical rating scale used to assess the severity of obsessive-compulsive disorder (OCD) symptoms.
  • Single nucleotide polymorphism (SNP): A variation in a single DNA building block that occurs at a specific position in the genome.
  • Val-158-Met polymorphism: A specific genetic variation in the COMT gene that can affect enzyme activity and potentially influence response to medications like Tolcapone.

References

  1. https://clinicaltrials.gov/study/NCT03591757
  2. https://clinicaltrials.gov/study/NCT06387771
  3. https://clinicaltrials.gov/study/NCT00927563
  4. https://clinicaltrials.gov/study/NCT02191826
  5. https://clinicaltrials.gov/study/NCT02652598
  6. https://clinicaltrials.gov/study/NCT03633591
  7. https://clinicaltrials.gov/study/NCT05624528
  8. https://clinicaltrials.gov/study/NCT02080715
  9. https://clinicaltrials.gov/study/NCT00044083
  10. https://clinicaltrials.gov/study/NCT00033059